AJUNTAMENT D'ALCOI
Website
Generalitat Valenciana
Website
Ayuntamiento de Valencia
Website
Cicloplast
Website
Ayuntamiento de Onil
Website
Anarpla
Website
Ayuntamiento de Mislata
Website
nlWA, North London Waste Authority
Website
Ayuntamiento de Salinas
Website
Zicla
Website
Fondazione Ecosistemi
Website
PEFC
Website
ALQUIENVAS
Website
DIPUTACI� DE VAL�NCIA
Website
AYUNTAMIENTO DE REQUENA
Website
UNIVERSIDAD DE ZARAGOZA
Website
OBSERVATORIO CONTRATACIÓN PÚBLICA
Website
AYUNTAMIENTO DE PAIPORTA
Website
AYUNTAMIENTO DE CUENCA
Website
BERL� S.A.
Website
CM PLASTIK
Website
TRANSFORMADORES INDUSTRIALES ECOL�GICOS
INDUSTRIAS AGAPITO
Website
RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Discovery of new and highly effective quadruple FFA1 and PPAR?/?/? agonists as potential anti-fatty liver agents
Non-alcoholic fatty liver disease (NAFLD) has become the most common hepatic disease, while no drug was approved until now. The previous study reported that the quadruple FFA1/PPAR-?/?/? agonist RLA8 provided better efficacy than obeticholic acid on NASH. In the present study, two design strategies were introduced to explore better quadruple FFA1/PPAR-?/?/? agonists with improved metabolic stability. These efforts ultimately resulted in the identification of ZLY18, a quadruple FFA1/PPAR-?/?/? agonist with twice higher metabolic half-life than RLA8 in the liver microsome. In the triton-1339W-induced hyperlipidemic model, ZLY18 reversed hyperlipidemia to an almost normal level, which exhibited far stronger lipid-lowering effects than that of RLA8. Moreover, ZLY18 significantly decreased steatosis, hepatocellular ballooning, inflammation and liver fibrosis in NASH model even better than RLA8. Further mechanism studies suggested that ZLY18 exerts stronger effects than RLA8 on the regulation of the gene related to lipid synthesis, oxidative stress, inflammation and fibrosis. In addition, ZLY18 is more effective than pirfenidone in the prevention of CCl4-induced liver fibrosis. Besides, ZLY18 has an acceptable safety profile in the acute toxicity study at a high dose of 500?mg/kg. Therefore, ZLY18 represents a novel and highly promising quadruple FFA1/PPAR-?/?/? agonist worth of further investigation and development.
» Author: Zongtao Zhou, Qiang Ren, Shixuan Jiao, Zongyu Cai, Xinqian Geng, Liming Deng, Bin Wang, Lijun Hu, Luyong Zhang, Ying Yang, Zheng Li
» Publication Date: 05/02/2022
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es